GC Medical Science, Yuwell Target CGM Market
Predicted impact: Low· Actual: −3.9% vs sector, volume 2.1× normal (5 trading days)
Partnership to introduce a Chinese CGM device; no deal size or revenue impact disclosed.
GC Medical Science녹십자엠에스
142280 · KOSDAQ · ₩142280 · 녹십자엠에스
₩3,280▲ ₩30 (0.92%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −20.00%
- Market cap
- ₩79B
- Enterprise value
- ₩87B
- P/E
- —
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- −4.0%
- Net margin
- −2.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−50.8% from the high
₩2,200Today: ₩3,230 – ₩3,350₩6,660
Returns
- 1W−18.0%
- 1M+4.0%
- 3M+29.6%
- 6M−15.8%
- YTD−18.1%
- 1Y−20.0%
- Volume today
- 598,774
- 0.1× the 20-day average
- Traded today
- ₩2B
- Listed shares
- 23,963,031
- EPS (12 months)
- −₩90
- Earnings yield −2.8%
AI research · InitiationGC Medical Science: Sharp Three-Month Rally, Thin Margins and a First-Half LossThe data shows a small, thinly profitable company whose share price has risen sharply on partnership news while the latest trailing results turned to a loss.Read the full report →
Upcoming dates
- Nov 2Earnings Expected · Preliminary results
- Nov 16Earnings Expected · 3Q results
- Jan 25Earnings Expected · Preliminary results
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 27 of 100 (50 is a normal day for this stock).
- MomentumFlat2.3% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
GC Medical Science stock overview
GC Medical Science (녹십자엠에스, KRX: 142280) is listed on KOSDAQ, in the Biotech & Pharma sector. The company operates in-vitro diagnostics, blood glucose monitoring, and hemodialysis solutions in Korea. Its shares closed at ₩3,280 on Oct 27, 2026, up 0.92% on the day, giving it a market value of ₩79B.
Key facts
- Market cap
- ₩79B
- Sector
- Biotech & Pharma
- Latest price change
- +0.92%
- As of
- Oct 27, 2026
- Main business
- The company operates in-vitro diagnostics, blood glucose monitoring, and hemodialysis solutions in Korea.
Quick answers about GC Medical Science
- What does GC Medical Science do?
- The company operates in-vitro diagnostics, blood glucose monitoring, and hemodialysis solutions in Korea. Its diagnostic reagents cover immunology, clinical chemistry and molecular diagnostics, and it sells to hospitals, clinics, public health centers, and pharmaceutical and medical supply wholesalers. The company also produces hemodialysis fluid for patients with chronic kidney failure at its Eumseong plant in Chungcheongbuk-do, and it sells blood glucose meters and HbA1c and lipid testing products.
- What is the market cap of GC Medical Science?
- The market capitalisation of GC Medical Science was ₩79B at the close on Oct 27, 2026.
- Who are the largest shareholders of GC Medical Science?
- According to the latest official filings, the largest reported holders are GC Pharma (47.00%, as of Jul 1, 2026); Timefolio Asset Management (12.96%, as of Aug 7, 2026); Kim Yeon-geun (0.19%, as of Oct 28, 2026).
- When is the next earnings report from GC Medical Science?
- Korean companies rarely announce results dates in advance. Based on when GC Medical Science filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company operates in-vitro diagnostics, blood glucose monitoring, and hemodialysis solutions in Korea. Its diagnostic reagents cover immunology, clinical chemistry and molecular diagnostics, and it sells to hospitals, clinics, public health centers, and pharmaceutical and medical supply wholesalers. The company also produces hemodialysis fluid for patients with chronic kidney failure at its Eumseong plant in Chungcheongbuk-do, and it sells blood glucose meters and HbA1c and lipid testing products.
Written by AI from the company's latest annual report.
- Korean name
- 녹십자엠에스
- Sector
- Biotech & Pharma
- Themes
- Medical devices
- CEO
- 김연근
- Founded
- Dec 2003
- Listed
- Dec 2014
- Listed shares
- 23,963,031
- Fiscal year ends
- Month 12
- Website
- www.greencrossms.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
GC녹십자엠에스, 중국 유웰과 맞손
Predicted impact: Low· Actual: −3.9% vs sector, volume 2.1× normal (5 trading days)
Partnership to introduce Chinese glucose monitor; small company, already reported in last 14 days.
GC Green Cross MS pursues domestic introduction of continuous glucose monitor with China's Yuwell
Predicted impact: Low· Actual: −3.9% vs sector, volume 2.1× normal (5 trading days)
Introduction of Chinese continuous glucose monitors already reported in last 14 days.
Recent filings
See all- Insider shareholding reportOct 28, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportAug 7, 2026
- Preliminary earnings (consolidated)Jul 31, 2026
- Adjustment of Exercise Price of WarrantsJul 20, 2026
Titles in Korean until English translations are added.
Also known as: GC Medical Science / 녹십자엠에스 / 142280 / KRX:142280
Source: KRX statistical information